



## **Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference**

August 5, 2025

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Aug. 5, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, August 12, 2025

Time: 1:30 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio's website at <http://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

### **About Adicet Bio, Inc.**

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20250805508642/en/>

### **Adicet Bio, Inc.**

#### **Investor and Media Contacts**

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Penelope Belnap

Precision AQ

212-362-1200

[Penelope.belnap@precisionaq.com](mailto:Penelope.belnap@precisionaq.com)

Source: Adicet Bio, Inc.